Adam L. Halberstadt

Adam L. Halberstadt

Auto-generated profile, based on publicly available information

Adam L. Halberstadt

Department of Psychiatry, University of California San Diego, La Jolla, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Behavioural Brain Research
Verified
Journal Article
Closed access
AHAdam L. Halberstadt
Adam L. Halberstadt

7 January 2020 in Neuropharmacology
Verified
Journal Article
Closed access
AHAdam L. Halberstadt
Adam L. Halberstadt
MCMuhammad Chatha
Muhammad Chatha
AKAdam K. Klein
Adam K. Klein
JWJason Wallach
Jason Wallach
SBSimon Brandt
Simon Brandt

15 December 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJason Wallach
Jason Wallach
ACAndrew B. Cao
Andrew B. Cao
MCMaggie M. Calkins
Maggie M. Calkins
AHAndrew J. Heim
Andrew J. Heim
JLJanelle K. Lanham
Janelle K. Lanham
JMJohn D. McCorvy
John D. McCorvy
Serotonergic psychedelics possess considerable therapeutic potential. Although 5-HT2A receptor activation mediates psychedelic effects, prototypical psychedelics activate both 5-HT2A-Gq/11 and β-arrestin2 transducers, making their respective roles unclear. To elucidate this, we develop a series of 5-HT2A-selective ligands with varying Gq efficacies, including β-arrestin-biased ligands. We show that 5-HT2A-Gq but not 5-HT2A-β-arrestin2 recruitment efficacy predicts psychedelic potential, assessed using head-twitch response (HTR) magnitude in male mice. We further show that disrupting Gq-PLC signaling attenuates the HTR and a threshold level of Gq activation is required to induce psychedelic-like effects, consistent with the fact that certain 5-HT2A partial agonists (e.g., lisuride) are non-psychedelic. Understanding the role of 5-HT2A Gq-efficacy in psychedelic-like psychopharmacology permits rational development of non-psychedelic 5-HT2A agonists. We also demonstrate that β-arrestin-biased 5-HT2A receptor agonists block psychedelic effects and induce receptor downregulation and tachyphylaxis. Overall, 5-HT2A receptor Gq-signaling can be fine-tuned to generate ligands distinct from classical psychedelics.

6 March 2023 in Cell Reports
Verified
Journal Article
Open access
VLVern Lewis
Vern Lewis
EBEmma M. Bonniwell
Emma M. Bonniwell
JLJanelle K. Lanham
Janelle K. Lanham
AGAbdi Ghaffari
Abdi Ghaffari
HSHooshmand Sheshbaradaran
Hooshmand Sheshbaradaran
JMJohn D. McCorvy
John D. McCorvy
Hallucinations limit the widespread therapeutic use of psychedelics as rapid-acting antidepressants. Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) analog 2-bromo-LSD (2-Br-LSD) at >33 aminergic G protein-coupled receptors (GPCRs). 2-Br-LSD shows partial agonism at several aminergic GPCRs, including 5-HT2A and does not induce the head-twitch response (HTR) in mice, supporting its classification as a non-hallucinogenic 5-HT2A partial agonist. Unlike LSD, 2-Br-LSD lacks 5-HT2B agonism, an effect linked to cardiac valvulopathy. Additionally, 2-Br-LSD produces weak 5-HT2A β-arrestin recruitment and internalization in vitro and does not induce tolerance in vivo after repeated administration. In cultured rat cortical neurons, 2-Br-LSD induces dendritogenesis and spinogenesis, and increases active coping behaviour in mice, an effect blocked by the 5-HT2A-selective antagonist volinaserin (M100,907). 2-Br-LSD also reverses the behavioral effects of chronic stress. Overall, 2-Br-LSD has an improved pharmacological profile compared to LSD and may have profound therapeutic value for mood disorders and other indications.

1 January 2016
Verified
Book Chapter
Closed access
PDF file
AHAdam L. Halberstadt
Adam L. Halberstadt
MGMark A. Geyer
Mark A. Geyer

1 February 2014 in Neuropharmacology
Verified
Journal Article
Closed access
AHAdam L. Halberstadt
Adam L. Halberstadt
MGMark A. Geyer
Mark A. Geyer